Protecting U.S. Swine from ASFV
African Swine Fever Virus (ASFV) is a highly contagious, fatal disease in pigs that spreads rapidly. There is no commercially available treatment or vaccine for the virus, and it poses a significant threat to United States swine production, a $57-billion-dollar industry.
Without a preventative vaccine or treatment, producers’ only control options are enhancing biosecurity, increasing surveillance and quarantining or culling infected pigs. Producers need a way to protect their herds.
To address this urgent concern, Dr. Waithaka Mwangi, immunology professor in the Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine at Kansas State University (K-State), is developing and validating a vaccine to protect pigs from the virus. Existing research has shown that certain proteins inherent within the virus can activate protective immunity. This research is focused on identification of the protective ASFV proteins, identification of an effective vaccination method that will spur a protective immune response in pigs and validation of the prototype vaccine’s efficacy using a large sample size for the study.
ASFV has existed in Africa for decades, but it is now spreading due to changing production practices and increasing globalization. ASFV entered China in August 2018 and significantly disrupted the country’s pork industry for several years after. The virus is now infecting swine herds across the globe, with the closest outbreaks to the U.S. occurring in the Dominican Republic and Haiti.